Page 1081 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

4 References

93. Nguyen MH, Peacock JE Jr, Tanner DC, et al. Therapeutic 102. Johnson LB, Kauffman CA. Voriconazole: a new triazole anti-
approaches in patients with candidemia. Evaluation in a mul- fungal agent. Clin Infect Dis. 2003;36:630-637.
ticenter, prospective, observational study. Arch Intern Med. 103. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic
1995;155:2429-2435. drug monitoring in patients with invasive mycoses improves
94. Karlowicz MG, Hashimoto LN, Kelly RE, Buescher ES. Should efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-211.
central venous catheters be removed as soon as candidemia is 104. Groll AH, Schrey D, Walsh TJ. Echinocandins. In: Kauffman
detected in neonates? Pediatrics. 2000;106:E63. CA, Pappas PG, Sobel JD, Dismukes WE, eds. Essentials of
95. Nucci M, Anaissie E. Should vascular catheters be removed Clinical Mycology, 2nd ed. New York NY: Springer: 2011:95-112.
from all patients with candidemia? an evidence-based review. 105. Kauffman CA, Carver PL. Update on echinocandin antifungals.
Clin Infect Dis. 2002;34:591-599.
Semin Respir Crit Care Med. 2008;29:211-220.
96. Nucci M, Anaissie E, Betts RF, et al. Early removal of central
venous catheter in patients with candidemia does not improve 106. Glockner A, Steinbacj A, Vehreschild JJ, Cornely OA.
outcome: analysis of 842 patients from 2 randomized trials. Clin Treatment of invasive candidiasis with echinocandins. Mycoses.
Infect Dis. 2010;51:295-303. 2008;52:476-486.
97. Fisher JF, Sobel JD, Kauffman CA, Newman CA. Candida urinary 107. Bates DW, Su L, Yu CT, et al. Mortality and costs of acute renal
tract infections: Treatment. Clin Infect Dis. 2011;52: (in press) failure associated with amphotericin B therapy. Clin Infect Dis.
2001;32:686-693.
98. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the
ARTEMIS DISK Global Antifungal Surveillance Study, 1997 108. Alvarez-Lerma F, Marsical F, Quintana E, et al. Use of liposomal
to 2005: an 8.5-year analysis of susceptibilities of Candida and amphotericn B in critically ill patients: a retrospective, multi-
other yeast species to fluconazole and voriconazole determined center, clinical study. J Chemother. 2009;42:1289-1296.
by CLSI standardized disk diffusion testing. J Clin Microbiol. 109. Steinbach WJ. Antifungal agents in children. Pediatr Clin North
2007;45:1735-1745. Am. 2005;52:895-915.
99. Andes DR, Dismukes WE. Azoles. In: Kauffman CA, Pappas 110. Andes D, Safdar N, Marchillo K, Conklin R. Pharmacokinetic-
PG, Sobel JD, eds. Dismukes Essentials of Clinical Mycology, 2nd pharmacodynamic comparison of amphotericin B (AMB) and
ed. New York NY: Springer; 2011:61-94. two lipid-associated AMB preparations, liposomal AMB and
100. Bergman SJ, Tyagi I, Ronald K. Antifungal dosing in critically ill AMB lipid complex, in murine candidiasis models. Antimicrob
patients. Curr Fungal Infect Rep. 2010;4:78-86. Agents Chemother. 2006;50:674-684.
101. Panackal AA, Gribskov JL, Staab JF, et al. Clinical significance 111. Kauffman CA. Amphotericin B. In: Invasive fungal infections.
of azole antifungal drug cross-resistance in Candida glabrata. Sem Resp Crit Care Med Lynch JP (ed). Germany: Thieme
J Clin Microbiol. 2006;44:1740-1743. Publishing, 1997;18:281-287.

Section05-O-ref.indd 4 1/20/2015 4:51:22 PM